Politique publique : Questions médicales fréquentes
Nom anglais: Public Policy
Descriptor UI:D011640
Tree Number:N03.623.500.608
Termes MeSH sélectionnés :
Sleep Initiation and Maintenance Disorders
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Politique publique : Questions médicales les plus fréquentes",
"headline": "Politique publique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Politique publique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-16",
"dateModified": "2025-03-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Politique publique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Politiques de régulation sociale",
"url": "https://questionsmedicales.fr/mesh/D011049",
"about": {
"@type": "MedicalCondition",
"name": "Politiques de régulation sociale",
"code": {
"@type": "MedicalCode",
"code": "D011049",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Politique de planification familiale",
"alternateName": "Family Planning Policy",
"url": "https://questionsmedicales.fr/mesh/D016656",
"about": {
"@type": "MedicalCondition",
"name": "Politique de planification familiale",
"code": {
"@type": "MedicalCode",
"code": "D016656",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.214"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Politique de santé",
"alternateName": "Health Policy",
"url": "https://questionsmedicales.fr/mesh/D006291",
"about": {
"@type": "MedicalCondition",
"name": "Politique de santé",
"code": {
"@type": "MedicalCode",
"code": "D006291",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Politique nutritionnelle",
"alternateName": "Nutrition Policy",
"url": "https://questionsmedicales.fr/mesh/D018673",
"about": {
"@type": "MedicalCondition",
"name": "Politique nutritionnelle",
"code": {
"@type": "MedicalCode",
"code": "D018673",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.650"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apports nutritionnels recommandés",
"alternateName": "Recommended Dietary Allowances",
"url": "https://questionsmedicales.fr/mesh/D064167",
"about": {
"@type": "MedicalCondition",
"name": "Apports nutritionnels recommandés",
"code": {
"@type": "MedicalCode",
"code": "D064167",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.650.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apports nutritionnels recommandés",
"alternateName": "Recommended Dietary Allowances",
"url": "https://questionsmedicales.fr/mesh/D064167",
"about": {
"@type": "MedicalCondition",
"name": "Apports nutritionnels recommandés",
"code": {
"@type": "MedicalCode",
"code": "D064167",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.650.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Contrôle du tabac",
"alternateName": "Tobacco Control",
"url": "https://questionsmedicales.fr/mesh/D000092843",
"about": {
"@type": "MedicalCondition",
"name": "Contrôle du tabac",
"code": {
"@type": "MedicalCode",
"code": "D000092843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.825"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Politique anti-tabac",
"alternateName": "Smoke-Free Policy",
"url": "https://questionsmedicales.fr/mesh/D061845",
"about": {
"@type": "MedicalCondition",
"name": "Politique anti-tabac",
"code": {
"@type": "MedicalCode",
"code": "D061845",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.825.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Prévention du fait de fumer",
"alternateName": "Smoking Prevention",
"url": "https://questionsmedicales.fr/mesh/D000074606",
"about": {
"@type": "MedicalCondition",
"name": "Prévention du fait de fumer",
"code": {
"@type": "MedicalCode",
"code": "D000074606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.825.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Politique anti-tabac",
"alternateName": "Smoke-Free Policy",
"url": "https://questionsmedicales.fr/mesh/D061845",
"about": {
"@type": "MedicalCondition",
"name": "Politique anti-tabac",
"code": {
"@type": "MedicalCode",
"code": "D061845",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.825.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Prévention du fait de fumer",
"alternateName": "Smoking Prevention",
"url": "https://questionsmedicales.fr/mesh/D000074606",
"about": {
"@type": "MedicalCondition",
"name": "Prévention du fait de fumer",
"code": {
"@type": "MedicalCode",
"code": "D000074606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.623.500.608.428.825.750"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Politique publique",
"alternateName": "Public Policy",
"code": {
"@type": "MedicalCode",
"code": "D011640",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Krystyna Kongats",
"url": "https://questionsmedicales.fr/author/Krystyna%20Kongats",
"affiliation": {
"@type": "Organization",
"name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada."
}
},
{
"@type": "Person",
"name": "Jennifer Ann McGetrick",
"url": "https://questionsmedicales.fr/author/Jennifer%20Ann%20McGetrick",
"affiliation": {
"@type": "Organization",
"name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada."
}
},
{
"@type": "Person",
"name": "Kim D Raine",
"url": "https://questionsmedicales.fr/author/Kim%20D%20Raine",
"affiliation": {
"@type": "Organization",
"name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada."
}
},
{
"@type": "Person",
"name": "Sonja Grelle",
"url": "https://questionsmedicales.fr/author/Sonja%20Grelle",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Psychology, Ruhr University Bochum."
}
},
{
"@type": "Person",
"name": "Wilhelm Hofmann",
"url": "https://questionsmedicales.fr/author/Wilhelm%20Hofmann",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Psychology, Ruhr University Bochum."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.",
"datePublished": "2024-02-16",
"url": "https://questionsmedicales.fr/article/38707815",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ekir.2024.02.1395"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bilateral Lumbosacral Plexopathy As the Initial Manifestation of Systemic Sarcoidosis: A Case Report.",
"datePublished": "2024-02-12",
"url": "https://questionsmedicales.fr/article/38487149",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.54086"
}
},
{
"@type": "ScholarlyArticle",
"name": "Catalytic Aminium Radical-Cation Salt (Magic Blue)-Initiated S",
"datePublished": "2024-02-07",
"url": "https://questionsmedicales.fr/article/38323416",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.joc.3c02194"
}
},
{
"@type": "ScholarlyArticle",
"name": "Household Income and Subsequent Youth Tobacco Initiation: Minorities' Diminished Returns.",
"datePublished": "2024-02-02",
"url": "https://questionsmedicales.fr/article/38425566",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.glmedi.2024.100063"
}
},
{
"@type": "ScholarlyArticle",
"name": "Walking the talk for dementia: A unique immersive, embodied, and multi-experiential initiative.",
"datePublished": "2024-01-26",
"url": "https://questionsmedicales.fr/article/38275208",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/alz.13644"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Organisations et économie des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D004472"
},
{
"@type": "ListItem",
"position": 3,
"name": "Politique (principe)",
"item": "https://questionsmedicales.fr/mesh/D057766"
},
{
"@type": "ListItem",
"position": 4,
"name": "Politiques de régulation sociale",
"item": "https://questionsmedicales.fr/mesh/D011049"
},
{
"@type": "ListItem",
"position": 5,
"name": "Politique publique",
"item": "https://questionsmedicales.fr/mesh/D011640"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Politique publique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Politique publique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Politique publique",
"description": "Comment évaluer l'impact d'une politique publique en santé ?\nQuels outils sont utilisés pour le diagnostic des politiques ?\nQuelles sont les méthodes d'analyse des politiques publiques ?\nComment identifier les besoins de santé dans une communauté ?\nQuel rôle joue la recherche dans le diagnostic des politiques ?",
"url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Politique publique",
"description": "Quels symptômes indiquent un échec de la politique publique ?\nComment mesurer les symptômes de l'inefficacité des politiques ?\nQuels indicateurs de santé révèlent des problèmes systémiques ?\nComment les symptômes sociaux affectent-ils la santé publique ?\nQuels symptômes peuvent signaler un besoin de réforme ?",
"url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Politique publique",
"description": "Quelles stratégies de prévention sont efficaces en politique publique ?\nComment évaluer l'efficacité des programmes de prévention ?\nQuels obstacles à la prévention sont souvent rencontrés ?\nComment les politiques publiques peuvent-elles promouvoir la prévention ?\nQuel rôle joue l'éducation dans la prévention des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Politique publique",
"description": "Comment les politiques influencent-elles les traitements disponibles ?\nQuels traitements sont souvent négligés par les politiques publiques ?\nComment évaluer l'efficacité des traitements en politique publique ?\nQuel est l'impact des politiques sur les traitements préventifs ?\nComment les politiques de santé affectent-elles les traitements psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Politique publique",
"description": "Quelles complications peuvent résulter d'une mauvaise politique de santé ?\nComment les complications de santé sont-elles liées aux politiques publiques ?\nQuels sont les effets à long terme d'une politique de santé défaillante ?\nComment prévenir les complications liées aux politiques de santé ?\nQuel rôle jouent les données dans la prévention des complications ?",
"url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Politique publique",
"description": "Quels facteurs de risque sont souvent négligés par les politiques ?\nComment les politiques peuvent-elles réduire les facteurs de risque ?\nQuel impact a l'environnement sur les facteurs de risque ?\nComment les politiques de santé abordent-elles les facteurs de risque ?\nQuels sont les facteurs de risque liés aux comportements ?",
"url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'impact d'une politique publique en santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact se mesure par des indicateurs de santé, des études d'impact et des analyses de données."
}
},
{
"@type": "Question",
"name": "Quels outils sont utilisés pour le diagnostic des politiques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des enquêtes, des analyses statistiques et des études de cas sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quelles sont les méthodes d'analyse des politiques publiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les méthodes incluent l'analyse qualitative, quantitative et l'analyse coût-bénéfice."
}
},
{
"@type": "Question",
"name": "Comment identifier les besoins de santé dans une communauté ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des enquêtes, des focus groups et l'analyse des données de santé existantes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la recherche dans le diagnostic des politiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La recherche fournit des données probantes pour orienter les décisions politiques et évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un échec de la politique publique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inégalités de santé croissantes et une augmentation des maladies évitables peuvent indiquer un échec."
}
},
{
"@type": "Question",
"name": "Comment mesurer les symptômes de l'inefficacité des politiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "En analysant les taux de morbidité, mortalité et l'accès aux soins de santé."
}
},
{
"@type": "Question",
"name": "Quels indicateurs de santé révèlent des problèmes systémiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les taux de vaccination, d'obésité et de maladies chroniques sont des indicateurs clés."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sociaux affectent-ils la santé publique ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des problèmes comme la pauvreté et le chômage aggravent les conditions de santé et l'accès aux soins."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent signaler un besoin de réforme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hausse des plaintes des citoyens et des résultats de santé dégradés peuvent signaler ce besoin."
}
},
{
"@type": "Question",
"name": "Quelles stratégies de prévention sont efficaces en politique publique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les campagnes de sensibilisation, les programmes de vaccination et l'éducation à la santé."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des programmes de prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des études d'impact, des indicateurs de santé et des analyses de coûts."
}
},
{
"@type": "Question",
"name": "Quels obstacles à la prévention sont souvent rencontrés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le manque de financement, l'accès limité aux soins et la désinformation sont des obstacles majeurs."
}
},
{
"@type": "Question",
"name": "Comment les politiques publiques peuvent-elles promouvoir la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "En intégrant des programmes de prévention dans les systèmes de santé et en finançant des initiatives."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'éducation dans la prévention des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation sensibilise la population aux comportements sains et aux risques de maladies."
}
},
{
"@type": "Question",
"name": "Comment les politiques influencent-elles les traitements disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les politiques déterminent le financement, l'accès et les protocoles de traitement en santé."
}
},
{
"@type": "Question",
"name": "Quels traitements sont souvent négligés par les politiques publiques ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements pour les maladies rares et les soins palliatifs sont souvent sous-financés."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des traitements en politique publique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des études cliniques, des revues systématiques et des analyses de coût-efficacité."
}
},
{
"@type": "Question",
"name": "Quel est l'impact des politiques sur les traitements préventifs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les politiques favorisent l'accès aux vaccinations et dépistages, réduisant ainsi les maladies."
}
},
{
"@type": "Question",
"name": "Comment les politiques de santé affectent-elles les traitements psychologiques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles influencent le financement et l'accès aux soins de santé mentale, souvent négligés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter d'une mauvaise politique de santé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inégalités de santé, une augmentation des maladies chroniques et un accès limité aux soins."
}
},
{
"@type": "Question",
"name": "Comment les complications de santé sont-elles liées aux politiques publiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des politiques inefficaces peuvent aggraver les conditions de santé et limiter l'accès aux traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme d'une politique de santé défaillante ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des coûts de santé, une détérioration de la santé publique et des inégalités croissantes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux politiques de santé ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "En évaluant régulièrement les politiques et en adaptant les programmes aux besoins de la population."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les données dans la prévention des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les données aident à identifier les problèmes, à évaluer les politiques et à orienter les interventions."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont souvent négligés par les politiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déterminants sociaux de la santé, comme la pauvreté et l'éducation, sont souvent sous-estimés."
}
},
{
"@type": "Question",
"name": "Comment les politiques peuvent-elles réduire les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "En promouvant des environnements sains, l'éducation et l'accès aux soins préventifs."
}
},
{
"@type": "Question",
"name": "Quel impact a l'environnement sur les facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement pollué ou peu sûr augmente les risques de maladies et affecte la santé publique."
}
},
{
"@type": "Question",
"name": "Comment les politiques de santé abordent-elles les facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles intègrent des stratégies de prévention et d'éducation pour réduire les risques de maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque liés aux comportements ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'alimentation malsaine et le manque d'activité physique sont des facteurs clés."
}
}
]
}
]
}
The approximately 70% 12-month relapse in children experiencing the initial episode of steroid-sensitive nephrotic syndrome (SSNS) is a significant concern, with over 50% developing frequent relapses ...
A prospective, multicenter, open-label, single-arm trial was conducted in China, with a 12-month follow-up. Children aged 1 to 18 years with the first episode of nephrotic syndrome (NS) were screened ...
Out of the initially 66 children screened, 44 were enrolled and received rituximab, with all but 1 participant completing the 12-month follow-up. The median age at diagnosis was 4.3 years (interquarti...
Our findings support that early administration of rituximab may be associated with a higher 12-month relapse-free survival and a reduced incidence of FRNS/SDNS in children experiencing the initial epi...
Neurosarcoidosis is one of the most relevant involvements in systemic sarcoidosis and can be the initial presentation. Its diagnosis is often considered difficult because of unusual clinical manifesta...
Household income, a prominent socioeconomic status (SES) indicator, is known to mitigate youth engagement in various health risk behaviors, including tobacco use. Nevertheless, the Minorities' Diminis...
Conducted as a longitudinal analysis, this study utilized data from the initial three years of the Adolescent Brain Cognitive Development (ABCD) Study spanning 2016-2022. The cohort consisted of 11,87...
Out of the 8,754 American youth who were non-smokers at baseline, 3.1% (n = 269) initiated tobacco use during the 30-month follow-up, while 96.9% (n = 8,485) remained non-smokers. A family income exce...
Within the United States, the racialization and minoritization of youth diminish the protective effects of economic resources, such as high household income, against the transition to tobacco use. Non...
Coping with dementia requires an integrated approach encompassing personal, health, research, and community domains. Here we describe "Walking the Talk for Dementia," an immersive initiative aimed at ...
Opioid use after kidney transplant has been associated with an increased risk of death and graft loss. Several transplant centers have reported reductions in opioid use using multimodal analgesia and ...
Clinicians form initial impressions about a child's diagnosis based on behavioral features, but research has not yet identified specific behaviors to guide initial diagnostic impressions. Participants...
Negative ulnar variance is a widely accepted risk factor for the development of Kienbock disease (KD). Variation in radial inclination has been proposed as a risk factor, but evidence thus far has bee...
A retrospective analysis of all KD patients from a single institution from 2007 to 2021 was conducted. Radiographs were reviewed to measure anatomic parameters and stage of disease. An exploratory mul...
Fifty-seven cases of KD were identified, with a mean duration of disease of 33.3 months. A history of trauma to the wrist was common (53%) and significantly associated with stage of disease at initial...
A correlation exists between decreased radial inclination and more advanced KD at presentation, suggesting this may be a risk factor for disease progression. This correlation is strengthened by our fi...
IV....
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by the destruction of the pancreatic beta cells, which produce insulin. Individuals with T1DM usually require at least 3-5 years to dev...
The pathogenesis of the development of microvascular complications in type 1 diabetes mellitus is multifactorial. The development of complications is seen at least a few years following the diagnosis....
Skills and knowledge gaps frequently exist between forensic educational programs and practical forensic laboratory needs. An educational outreach project involving three post-secondary academic instit...